Japan
Eisai Seeks Approval in Japan for Ultrahigh-Dose Mecobalamin in ALS
This application is based on the results of JETALS (The Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for ALS), a Phase III trial to evaluate e...
January 29, 2024 | News
PRISM BioLab Secures 1.5 Billion Yen in Series C Funding for Advancing Protein-Protein Interaction Technologies
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein int...
January 25, 2024 | News
Japan greenlights historic treatment for ultra-rare Progeria, marking a significant breakthrough in addressing rapid-aging diseases.
The Progeria Research Foundation (PRF) today announced a new milestone with the approval of Zokinvy™ (lonafarnib) by the Japanese Ministry of Health,...
January 22, 2024 | News
Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
In a significant move, Agappe and Fujirebio have revealed plans to launch these products in June 2024. The project has already achieved significant progres...
January 22, 2024 | News
Eisai's Fycompa Injection Approved in Japan, Paving the Way for Non-Oral Antiepileptic Treatment
Fycompa is a first-in-class AED discovered at Eisai’s Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor an...
January 20, 2024 | News
Canon Medical and Olympus Form Endoscopic Ultrasound Systems Alliance
Canon Medical has a history of more than 100 years in the diagnostic imaging systems business, including X-ray diagnostic systems, CT, MRI, and ultrasound ...
January 16, 2024 | News
Japan Approves Neurolief's Relivion®, Paving the Way for At-Home Migraine Treatment.
Relivion® is a novel, non-invasive multi-channel brain neuromodulation technology. It stands out by concurrently stimulating the occipital and tri...
January 12, 2024 | News
SyntheticGestalt and Enamine Partner for AI-Driven Drug Discovery Model
SyntheticGestalt, a research and development company specializing in the application of AI to the life sciences domain, and Enamine, the world's leading pr...
January 11, 2024 | News
AGC Biologics to Open New Manufacturing Site in Yokohama, Japan
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced plans to construct...
January 05, 2024 | News
Elpiscience, Astellas Ink Deal for Novel Bispecific Macrophage Engager
The two companies will collaboratively conduct early-stage research for these two programs. Elpiscience will also grant Astellas the right to add up ...
January 01, 2024 | News
AGC announces strategic expansion of its Biopharmaceutical CDMO capability in Yokohama, Japan, signaling a new era of innovation and growth
This expansion has been selected by the Japanese Ministry of Economy, Trade and Industry (METI) as part of its "Developing biopharmaceutical manufacturin...
December 26, 2023 | News
Astellas Completes Acquisition of Propella Therapeutics
Through the acquisition of Propella, Astellas has acquired PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor being develope...
December 22, 2023 | News
Biocon Biologics Successfully Integrates Acquired Biosimilars Business Across 120 Countries
Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully conc...
December 19, 2023 | News
Fosun Pharma's Antimalarial Drug Trial Gets 500 Million Yen Boost from GHIT Fund for Global Accessibility Initiative
The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced that it will invest approximately US$3.3 million (approximate...
December 15, 2023 | News
Most Read
- Why Cell Therapy Systems Are Going Automatic: A New Era of Manufacturing
- Pioneering Precision: Top 15 Clinical and Lab Diagnostic Companies to Watch in 2025
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
- James Park Joins South Korean LOTTE BIOLOGICS as New CEO to Lead Global Expansion
- Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria
- Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production
- Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds
News
